Recent researches have shown that MEK is an attractive target for the treatment of cancer.
Aberrant signalling through MEK cellular pathway has been shown to lead to unconstrained cell proliferation and cell transformation and is a characteristic feature of many cancers.
Data suggest that targeting MEK, may inhibit cancer signalling mediated by a wide variety of signals, making MEK and attractive target for the treatment of cancer.
This new molecule could increase until 5 months the survival free progression of the patients (in any case this is the hypothesis of the primary study end point) for which the targeted therapeutics options are limited.
The eligible patients for the MILO study, are females of 18 years or older with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum.
Recruitment is now starting and last for around 18 months. The CHEM hospital is one of the recruiting sites with the participation of the CIEC. Additional information on this trial is available on our website under following link: www.luxclin.lu/Studies/Details/?c=STP6370KSE
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.